HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders.

20 years in CNS pharmacology training, Cancer, Divorce and grief recovery, lover of doodles and fishing self care/maintenance. Peer: Substance Abuse 35 years of Sobriety & 12 Step experience.

The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Objective: As neuropsychiatric conditions can increase the risk of age-related neurodegenerative diseases (NDDs), the impact of CNS-active drugs on the risk of developing Alzheimer’s Disease (AD), non ...

The acquisition will augment Gate Neurosciences’ existing translational research in synaptic function pharmacology ... next-generation precision CNS treatments that address growing needs ...

Feb. 11, 2025 — A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way ...

Gate Neurosciences today announced it has entered a definitive agreement to acquire Boost Neuroscience and its leading proprietary platform for human synapse network analysis and synapse-targeted drug ...